{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:05:42Z","timestamp":1779509142038,"version":"3.53.1"},"reference-count":44,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,4,30]]},"DOI":"10.5582\/ddt.2026.01008","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:10:09Z","timestamp":1777241409000},"page":"175-189","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study)"],"prefix":"10.5582","volume":"20","author":[{"given":"Toshimasa","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ya","family":"Kawashiri","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."},{"name":"Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiko","family":"Morita","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Tashiro","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuntaro","family":"Sato","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moemi","family":"Yabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Misaki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Kita-Harima Medical Center, Hyogo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Hanai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Nakagomi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Ogasawara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aomori Prefectural Central Hospital, Aomori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanazawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Aomori Prefectural Central Hospital, Aomori, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Hakujyujikai Sasebo Chuo Hospital, Sasebo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Okano","sequence":"additional","affiliation":[{"name":"Center for Senile Degenerative Disorders (CSDD), Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahisa","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takaoka","sequence":"additional","affiliation":[{"name":"Section of Internal Medicine and Rheumatology, Kumamoto Shinto General Hospital, Kumamoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, NHO Miyakonojo Hospital, Miyazaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Institute of Rheumatology, Miyazaki-Zenjinkai Hospital, Miyazaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Furuta","sequence":"additional","affiliation":[{"name":"Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hosogaya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010; 376:1094-1108.","DOI":"10.1016\/S0140-6736(10)60826-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Smolen JS, Breedveld FC, Burmester GR, <i>et al<\/i>. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016; 75:3-15.","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Smolen JS, Landew\u00e9 RBM, Bergstra SA, <i>et al.<\/i> EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022; 82:3-18.","DOI":"10.1136\/ard-2022-223356corr1"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Harigai M, Kaneko Y, Tanaka E, <i>et al<\/i>. 2024 Update of the Japan College of Rheumatology Clinical Practice Guidelines for the Management of Rheumatoid Arthritis: Secondary publication. Mod Rheumatol. 2025; 35:387-401.","DOI":"10.1093\/mr\/roaf006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gadina M, Le MT, Schwartz DM, Silvennoinen O, Nakayamada S, Yamaoka K, O&apos;Shea JJ. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology (Oxford). 2019; 58:i4-i16.","DOI":"10.1093\/rheumatology\/key432"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Genovese MC, Kalunian K, Gottenberg JE, Mozaffarian N, Bartok B, Matzkies F, Gao J, Guo Y, Tasset C, Sundy JS, de Vlam K, Walker D, Takeuchi T. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial. JAMA. 2019; 322:315-325.","DOI":"10.1001\/jama.2019.9055"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Combe B, Kivitz A, Tanaka Y, <i>et al<\/i>. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021; 80:848-858.","DOI":"10.1136\/annrheumdis-2020-219214"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Fleischmann R, Pangan AL, Song IH, Mysler E, Bessette L, Peterfy C, Durez P, Ostor AJ, Li Y, Zhou Y, Othman AA, Genovese MC. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial. Arthritis Rheumatol. 2019; 71:1788-1800.","DOI":"10.1002\/art.41032"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Fleischmann RM, Genovese MC, Enejosa JV, Mysler E, Bessette L, Peterfy C, Durez P, Ostor A, Li Y, Song IH. Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response. Ann Rheum Dis. 2019; 78:1454-1462.","DOI":"10.1136\/annrheumdis-2019-215764"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Taylor PC, Keystone EC, van der Heijde D, <i>et al<\/i>. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2017; 376:652-662.","DOI":"10.1056\/NEJMoa1608345"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014; 53:2110-2118.","DOI":"10.1093\/rheumatology\/keu217"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kawashiri SY, Suzuki T, Nakashima Y, Horai Y, Okada A, Iwamoto N, Ichinose K, Tamai M, Arima K, Nakamura H, Origuchi T, Uetani M, Aoyagi K, Eguchi K, Kawakami A. Ultrasonographic examination of rheumatoid arthritis patients who are free of physical synovitis: power Doppler subclinical synovitis is associated with bone erosion. Rheumatology (Oxford). 2014; 53:562-569.","DOI":"10.1093\/rheumatology\/ket405"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Han J, Geng Y, Deng X, Zhang Z. Subclinical Synovitis Assessed by Ultrasound Predicts Flare and Progressive Bone Erosion in Rheumatoid Arthritis Patients with Clinical Remission: A Systematic Review and Metaanalysis. J Rheumatol. 2016; 43:2010-2018.","DOI":"10.3899\/jrheum.160193"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Zufferey P, Scherer A, Nissen MJ, Ciurea A, Tamborrini G, Brulhart L, Blumhardt S, Toniolo M, M\u00f6ller B, Ziswiler HR. Can Ultrasound Be Used to Predict Loss of Remission in Patients with RA in a Real-life Setting? A Multicenter Cohort Study. J Rheumatol. 2018; 45:887-894.","DOI":"10.3899\/jrheum.161193"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Colebatch AN, Edwards CJ, \u00d8stergaard M, <i>et al<\/i>. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013; 72:804-814.","DOI":"10.1136\/annrheumdis-2012-203158"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. D&apos;Agostino MA, Terslev L, Wakefield R, \u00d8stergaard M, Balint P, Naredo E, Iagnocco A, Backhaus M, Grassi W, Emery P. Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission. Ann Rheum Dis. 2016; 75:1902-1908.","DOI":"10.1136\/annrheumdis-2016-209646"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310:2191-2194.","DOI":"10.1001\/jama.2013.281053"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Shimizu T, Kawashiri SY, Morimoto S, Kawazoe Y, Kuroda S, Kawasaki R, Ito Y, Kiya R, Sato S, Yamamoto H, Kawakami A. Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial. Trials. 2023; 24:161.","DOI":"10.1186\/s13063-023-07176-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Aletaha D, Neogi T, Silman AJ, <i>et al<\/i>. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62:2569-2581.","DOI":"10.1002\/art.27584"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Prevoo ML, van &apos;t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38:44-48.","DOI":"10.1002\/art.1780380107"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23:137-145.","DOI":"10.1002\/art.1780230202"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Torp-Pedersen ST, Terslev L. Settings and artefacts relevant in colour\/power Doppler ultrasound in rheumatology. Ann Rheum Dis. 2008; 67:143-149.","DOI":"10.1136\/ard.2007.078451"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. D&apos;Agostino MA, Boers M, Wakefield RJ, Berner Hammer H, Vittecoq O, Filippou G, Balint P, M\u00f6ller I, Iagnocco A, Naredo E, \u00d8stergaard M, Gaillez C, Le Bars M. Exploring a new ultrasound score as a clinical predictive tool in patients with rheumatoid arthritis starting abatacept: Results from the APPRAISE study. RMD Open. 2016; 2:e000237.","DOI":"10.1136\/rmdopen-2015-000237"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tanaka Y, Oba K, Koike T, <i>et al.<\/i> Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial. Ann Rheum Dis. 2020; 79:94-102.","DOI":"10.1136\/annrheumdis-2019-216169"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. van der Heijde D. How to read radiographs according to the Sharp\/van der Heijde method. J Rheumatol. 2000; 27:261-263.","DOI":"10.1097\/00002281-200007000-00005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 2004; 50:1761-1769.","DOI":"10.1002\/art.20303"},{"key":"27","unstructured":"27. Mee RW. Confidence bounds for the difference between two probabilities. Biometrics. 1984; 40:1175-1176."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Fleischmann R, Mysler E, Hall S, <i>et al<\/i>. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017; 390:457-468.","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, van Hoogstraten H, Bauer D, Ignacio Vargas J, Lee EB. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017; 76:840-847.","DOI":"10.1136\/annrheumdis-2016-210310"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, Kavanaugh A. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013; 381:1541-1550.","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Asai S, Takahashi N, Kobayakawa T, <i>et al<\/i>. Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis. Clin Rheumatol. 2021; 40:3143-3151.","DOI":"10.1007\/s10067-021-05815-3"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Strand V, Lee EB, Yazici Y, Dikranian A, Wilkinson B, Takiya L, Zang C, Bananis E, Bergman MJ. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clin Rheumatol. 2018; 37:2043-2053.","DOI":"10.1007\/s10067-018-4077-3"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Eberhard A, Bergman S, Mandl T, Olofsson T, Sharma A, Turesson C. Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients. Rheumatology (Oxford). 2024; 63:734-741.","DOI":"10.1093\/rheumatology\/kead278"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Rubbert-Roth A, Enejosa J, Pangan AL, Haraoui B, Rischmueller M, Khan N, Zhang Y, Martin N, Xavier RM. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020; 383:1511-1521.","DOI":"10.1056\/NEJMoa2008250"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Bingham CO, 3rd, Walker D, Nash P, Lee SJ, Ye L, Hu H, Khalid JM, Combe B. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Res Ther. 2022; 24:11.","DOI":"10.1186\/s13075-021-02677-7"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Nishino A, Kawashiri SY, Koga T, <i>et al<\/i>. Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan. Arthritis Care Res (Hoboken). 2018; 70:1719-1726.","DOI":"10.1002\/acr.23551"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Endo Y, Kawashiri SY, Nishino A, <i>et al.<\/i> Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan. Scand J Rheumatol. 2022; 51:259-267.","DOI":"10.1080\/03009742.2021.1927389"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Brown AK, Conaghan PG, Karim Z, Quinn MA, Ikeda K, Peterfy CG, Hensor E, Wakefield RJ, O&apos;Connor PJ, Emery P. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum. 2008; 58:2958-2967.","DOI":"10.1002\/art.23945"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Raffeiner B, Grisan E, Botsios C, Stramare R, Rizzo G, Bernardi L, Punzi L, Ometto F, Doria A. Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor \u03b1. Rheumatology (Oxford). 2017; 56:1320-1325.","DOI":"10.1093\/rheumatology\/kex084"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O&apos;Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006; 54:3761-3773.","DOI":"10.1002\/art.22190"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Ten Cate DF, Luime JJ, Swen N, Gerards AH, De Jager MH, Basoski NM, Hazes JM, Haagsma CJ, Jacobs JW. Role of ultrasonography in diagnosing early rheumatoid arthritis and remission of rheumatoid arthritis--a systematic review of the literature. Arthritis Res Ther. 2013; 15:R4.","DOI":"10.1186\/ar4132"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008; 112:3959-3964.","DOI":"10.1182\/blood-2008-05-155846"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Zhang X, Georgy A, Rowell L. Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects. Int J Clin Pharmacol Ther. 2013; 51:443-455.","DOI":"10.5414\/CP201819"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, Germino R, Menon S, Sun Y, Wang C, Shapiro AB, Kanik KS, Connell CA. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386:316-326.","DOI":"10.1056\/NEJMoa2109927"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/2\/20_2026.01008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T03:28:25Z","timestamp":1779506905000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/2\/20_2026.01008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01008","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"article-number":"2026.01008"}}